Navigation Links
Diabetic nerve therapy shows 'striking' results

Research into a new treatment for nerve damage caused by diabetes could bring relief to millions of diabetic patients, say experts.

The treatment might also reduce the number of amputations of toes and feet if early effects on nerve protection and regeneration are borne out long-term. Nerve disease in diabetes is the major cause of non-traumatic lower limb amputations in Europe and North America.

Scientists at The University of Manchester, working with colleagues at American biotech firm Sangamo BioSciences Inc, have discovered a way of stimulating genes that prevent nerve damage caused by the disease.

Professor David Tomlinson, who is leading the research in Manchester, says the study has massive potential for the management of diabetic neuropathies or nerve disorders.

"Diabetic neuropathy is a major problem in insulin-dependent diabetes, particularly in patients who have had the disease for a period of time," said Professor Tomlinson, who is based in the University's Faculty of Life Sciences.

"This approach to gene therapy is quite different to previous attempts at treatment as we do not inject a gene that produces a 'foreign' copy of a therapeutic protein. This is the normal approach and has problems from immunological side-effects.

"Instead, we turn on the patient's own gene to produce a natural version of this therapeutically beneficial protein. The most significant advantage of this is that the protein is made as if the patient's body had made it naturally.

"Our study has shown that a single treatment with a DNA-binding protein protected against nerve damage that in humans can lead to limb loss."

The results of the pre-clinical studies were recently presented to the American Diabetes Association in California and the first phase of clinical trials has now begun.

An estimated 50 per cent of patients with long-term diabetes develop some form of neuropathy that can cause numbness and sometimes pain and weakness in the hands, arms, feet and legs.

Currently, patients are treated with painkillers and antidepressants that do not treat the underlying nerve damage. Progression to amputation is not inevitable but is always a threat.

Problems may also occur in other organs, including the heart, kidneys, sex organs, eyes and digestive tract.

The incidence of diabetes, a condition in which the amount of glucose in the blood is too high, is increasing dramatically, with the World Health Organisation estimating that some 300 million people worldwide could be affected by 2025.

The causes of diabetic neuropathy are not fully understood but researchers investigating the effect of glucose on nerves believe it is likely to be a combination of factors.

Sangamo's Chief Medical Officer, Dr Dale Ando, said: "We have been greatly encouraged by Professor Tomlinson's data and have moved the programme into the clinic.

"The first phase of human trials will assess safety and examine the effects of a single treatment in one leg compared with a placebo treatment in the other leg."

The Diabetes and Glandular Disease Clinic in San Antonio, Texas, is involved in the clinical trials.

Dr Mark Kipnes, a clinical investigator for Sangamo and endocrinologist at the clinic, said: "Currently, there are no effective therapies available to treat this debilitating and frequent complication of diabetes and patients are generally prescribed painkillers to alleviate symptoms.

"We are excited to be involved in testing this novel approach that may potentially have a dramatic therapeutic effect in populations of patients already suffering from neuropathy and those that are at risk of developing it."


'"/>

Source:University of Manchester


Related biology news :

1. World-first Living Donor Islet Cell Transplant A Success; Procedure Offers Promise For Diabetics
2. Wisconsin scientists grow critical nerve cells
3. Clam embryo study shows pollutant mixture adversely affects nerve cell development
4. Zebrafish may hold key to understanding human nerve cell development
5. New component of the brakes on nerve regeneration found
6. Cerebral navigation: How do nerve fibers know what direction to grow in?
7. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
8. Malfunctioning bone marrow cells sabotage nerve cells in diabetes
9. UIC researchers show protein routes messages in nerve cells
10. Researchers find molecule that inhibits regrowth of spinal nerve cells
11. Gradient guides nerve growth down spinal cord
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/8/2016)... PUNE, India , Dec. 8, 2016 Market Research ... and Service Market. The global Mobile Biometric Security and Service Market ... period 2016 to 2022. Market Highlights: ... , , ... fast pace due to the increasing need of authentication and security ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , ... expansion of its patent portfolio, which grew to over 40 granted and ... , , ... recently filed patent entitled " System, Device, and Method Estimating ... that enables device makers to forego costly hardware components needed to estimate ...
Breaking Biology News(10 mins):
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions ... (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive ... their applicability in drug safety assessment, for the industry as a whole. , ...
(Date:1/17/2017)... COLUMBUS, Ohio , Jan. 17, 2017  On ... with the 35th Annual J.P. Morgan Healthcare Conference in ... Joseph D. Kittle, Jr. , spoke to pharmaceutical ... technology developed by ProclaRx to break down and destroy ... which protect bacteria and prevent antibiotics and the body,s ...
(Date:1/16/2017)... 16, 2017  Eurofins Genomics today announced the expansion ... customers to receive their primers in a shorter turnaround ... quality found with other providers. Express oligos are available ... at no additional fee. Researchers use ... including DNA sequencing, genotyping, site-directed mutagenesis, and cloning. Often, ...
Breaking Biology Technology: